These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9066342)

  • 1. Scopolamine patch can be confusing to the patient and anesthesiologist: a case report.
    Elias MA; Abouleish E
    Anesthesiology; 1997 Mar; 86(3):743-4. PubMed ID: 9066342
    [No Abstract]   [Full Text] [Related]  

  • 2. Transdermal scopolamine withdrawal syndrome.
    Feder RE
    Clin Neuropharmacol; 1999; 22(2):120. PubMed ID: 10202610
    [No Abstract]   [Full Text] [Related]  

  • 3. Transdermal hyoscine induced unilateral mydriasis.
    Hannon B; Jennings V; Twomey M; O'Reilly M
    BMJ Case Rep; 2012 Mar; 2012():. PubMed ID: 22605696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scopolamine for prevention of postoperative nausea in gynecologic laparoscopy, a randomized trial.
    Einarsson JI; Audbergsson BO; Thorsteinsson A
    J Minim Invasive Gynecol; 2008; 15(1):26-31. PubMed ID: 18262140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An unusual case of psychosis caused by long-term administration of a scopolamine membrane patch. Paranoid hallucinogenic and delusional symptoms].
    Rubner O; Kummerhoff PW; Haase H
    Nervenarzt; 1997 Jan; 68(1):77-9. PubMed ID: 9132625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I heard that the adhesive patch you can wear to prevent motion sickness is available again. Why was it taken off the market?
    Mayo Clin Health Lett; 1998 Mar; 16(3):8. PubMed ID: 9516375
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting.
    Gan TJ; Sinha AC; Kovac AL; Jones RK; Cohen SA; Battikha JP; Deutsch JS; Pergolizzi JV; ; Glass PS
    Anesth Analg; 2009 May; 108(5):1498-504. PubMed ID: 19372328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal scopolamine patch with odansetron for the control of nausea after uterine artery embolization compared with odansetron alone: results of a randomized placebo-controlled trial.
    Lee JS; Costantino M; McCullough MF; Lee JB; Jones MM; Carter EA; Spies JB
    J Vasc Interv Radiol; 2010 Jul; 21(7):1018-23. PubMed ID: 20537558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review.
    Kranke P; Morin AM; Roewer N; Wulf H; Eberhart LH
    Anesth Analg; 2002 Jul; 95(1):133-43, table of contents. PubMed ID: 12088957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal scopolamine for prevention of intrathecal morphine-induced nausea and vomiting after cesarean delivery.
    Harnett MJ; O'Rourke N; Walsh M; Carabuena JM; Segal S
    Anesth Analg; 2007 Sep; 105(3):764-9. PubMed ID: 17717237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal scopolamine and postoperative nausea and vomiting.
    Hendley BJ
    Anesthesiology; 1991 Jan; 74(1):198-9. PubMed ID: 1986653
    [No Abstract]   [Full Text] [Related]  

  • 12. Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting.
    Pergolizzi JV; Philip BK; Leslie JB; Taylor R; Raffa RB
    J Clin Anesth; 2012 Jun; 24(4):334-45. PubMed ID: 22608591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.
    Patel PN; Ezzo DC
    Am J Health Syst Pharm; 2009 Nov; 66(22):2024-6. PubMed ID: 19890085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central anticholinergic syndrome in a pediatric patient following transdermal scopolamine patch placement.
    Holland MS
    Nurse Anesth; 1992 Sep; 3(3):121-4. PubMed ID: 1445954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unilateral mydriasis caused by transdermal scopolamine.
    Rubin MM; Sadoff RS; Cozzi GM
    Oral Surg Oral Med Oral Pathol; 1990 Nov; 70(5):569-70. PubMed ID: 2234876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal scopolamine reduces nausea and vomiting after outpatient laparoscopy.
    Bailey PL; Streisand JB; Pace NL; Bubbers SJ; East KA; Mulder S; Stanley TH
    Anesthesiology; 1990 Jun; 72(6):977-80. PubMed ID: 2140929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diclegis for nausea and vomiting of pregnancy.
    Med Lett Drugs Ther; 2013 Aug; 55(1422):61-2. PubMed ID: 23917384
    [No Abstract]   [Full Text] [Related]  

  • 18. Transdermal scopolamine-induced neurologic deficits in patients with cancer.
    Friedberg MH; Glantz MJ
    R I Med; 1994 May; 77(5):141-2. PubMed ID: 8019013
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of transdermal hyoscine on nausea and vomiting.
    Foster RN
    Br J Anaesth; 1996 May; 76(5):749-50. PubMed ID: 8688287
    [No Abstract]   [Full Text] [Related]  

  • 20. Transdermal scopolamine use in the control of narcotic-induced nausea.
    Ferris FD; Kerr IG; Sone M; Marcuzzi M
    J Pain Symptom Manage; 1991 Aug; 6(6):389-93. PubMed ID: 1880439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.